Cargando…
Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer
Despite modest clinical improvement with anti-vascular endothelial growth factor antibody (AVA) therapy in ovarian cancer, adaptive resistance is ubiquitous and additional options are limited. A dependence on glutamine metabolism, via the enzyme glutaminase (GLS), is a known mechanism of adaptive re...
Autores principales: | Glassman, Deanna, Kim, Mark S., Spradlin, Meredith, Badal, Sunil, Taki, Mana, Bhattacharya, Pratip, Dutta, Prasanta, Kingsley, Charles V., Foster, Katherine I., Animasahun, Olamide, Jeon, Jin Heon, Achreja, Abhinav, Jayaraman, Anusha, Kumar, Praveen, Nenwani, Minal, Wuchu, Fulei, Bayraktar, Emine, Wu, Yutuan, Stur, Elaine, Mangala, Lingegowda, Lee, Sanghoon, Yap, Timothy A., Westin, Shannon N., Eberlin, Livia S., Nagrath, Deepak, Sood, Anil K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941132/ https://www.ncbi.nlm.nih.gov/pubmed/36824283 http://dx.doi.org/10.1016/j.isci.2023.106020 |
Ejemplares similares
-
Targeting CCR2(+) macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
por: Wu, Yutuan, et al.
Publicado: (2022) -
Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel
por: Han, Kai, et al.
Publicado: (2021) -
Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer
por: Lara, Olivia D., et al.
Publicado: (2020) -
Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer
por: Dasari, Santosh K., et al.
Publicado: (2023) -
Tumor-Reprogrammed Stromal BCAT1 Fuels Branched Chain Ketoacid Dependency in Stromal-Rich PDAC Tumors
por: Zhu, Ziwen, et al.
Publicado: (2020)